| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | MK-2206 | CTRPv2 | pan-cancer | AAC | -0.015 | 0.7 |
| mRNA | lenvatinib | CTRPv2 | pan-cancer | AAC | 0.015 | 0.7 |
| mRNA | KPT185 | CTRPv2 | pan-cancer | AAC | 0.016 | 0.7 |
| mRNA | linifanib | GDSC1000 | pan-cancer | AAC | 0.014 | 0.7 |
| mRNA | Vandetanib | FIMM | pan-cancer | AAC | -0.076 | 0.7 |
| mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | -0.013 | 0.7 |
| mRNA | MK-0752 | CTRPv2 | pan-cancer | AAC | -0.016 | 0.7 |
| mRNA | Doxorubicin | GDSC1000 | pan-cancer | AAC | -0.014 | 0.7 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.014 | 0.7 |
| mRNA | BRD-K27986637 | CTRPv2 | pan-cancer | AAC | -0.03 | 0.7 |